The relationship between renal function and plasma concentration of the cachectic factor zinc-alpha2-glycoprotein (ZAG) in adult patients with chronic kidney disease

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Pelletier, Caroline C ^a,b,c   Koppe, Laetitia ^a,b,c   Alix, Pascaline M ^a,b,c   Kalbacher, Emilie ^a,b,c   Croze, Marine L ^a,b   Hadj Aissa, Aoumeur ^a,c   Fouque, Denis ^a,b,d   Guebre Egziabher, Fitsum ^a,b,c   Soulage, Christophe O ^a,b  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ DE LYON   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLYCOPROTEIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG; UREA; ZINC; ZINC ALPHA2 GLYCOPROTEIN; SEMINAL PLASMA PROTEIN; ZN-ALPHA-2-GLYCOPROTEIN;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; INTERSTITIAL NEPHRITIS; KIDNEY CLEARANCE; KIDNEY POLYCYSTIC DISEASE; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; UREA BLOOD LEVEL; UROLITHIASIS; VERY ELDERLY; BLOOD; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; URINE;

ADULT; AGED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SEMINAL PLASMA PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 84905009141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103475     Document Type: Article

References (46)

1. Merabet E, Dagogo-Jack S, Coyne DW, Klein S, Santiago JV, et al (1997) Increased plasma leptin concentration in end-stage renal disease. J Clin Endocrinol Metab 82: 847-850. (Pubitemid 27106599)
2. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, et al (2002) Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13: 134-141. (Pubitemid 34042020)
3. Guebre-Egziabher F, Bernhard J, Funahashi T, Hadj-Aissa A, Fouque D (2005) Adiponectin in chronic kidney disease is related more to metabolic disturbances than to decline in renal function. Nephrol Dial Transplant 20: 129-134. (Pubitemid 40207617)
4. Stein S, Bachmann A, Lössner U, Kratzsch J, Blüher M, et al (2009) Serum levels of the adipokine FGF21 depend on renal function. Diabetes Care 32: 126-128.
5. Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Kratzsch J, et al (2007) Serum levels of adipokine retinol-binding protein-4 in relation to renal function. Diabetes Care 30: 2588-2592. (Pubitemid 47547801)
6. Pfau D, Bachmann A, Lössner U, Kratzsch J, Blüher M, et al (2010) Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 33: 171-173.
7. Burgi W, Schmid K (1961) Preparation and properties of Zn-alpha 2-glycoprotein of normal human plasma. J Biol Chem 236: 1066-1074.
8. Sánchez LM, Chirino AJ, Bjorkman Pj (1999) Crystal structure of human ZAG, a fat-depleting factor related to MHC molecules. Science 283: 1914-1919.
9. Russell ST, Zimmerman TP, Domin BA, Tisdale MJ (2004) Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim Biophys Acta 1636: 59-68. (Pubitemid 38231005)
10. Bing C (2011) Lipid mobilization in cachexia: mechanisms and mediators. Curr Opin Support Palliat Care 5: 356-360.
11. Tada T, Ohkubo I, Niwa M, Sasaki M, Tateyama H, et al (1991) Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem 39: 1221-1226.
12. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ (1998) Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 58: 2359-2365. (Pubitemid 28252695)
13. Russell ST, Tisdale MJ (2012) Role of β-adrenergic receptors in the anti-obesity and anti-diabetic effects of zinc-α2-glycoprotien (ZAG). Biochim Biophys Acta 1821: 590-599.
14. Russell ST, Hirai K, Tisdale MJ (2002) Role of beta3-adrenergic receptors in the action of a tumour lipid mobilizing factor. Br J Cancer 86: 424-428. (Pubitemid 34185128)
15. Gong F-Y, Zhang S-J, Deng J-Y, Zhu H-J, Pan H, et al (2009) Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond) 33: 1023-1030.
16. Sanders PM, Tisdale MJ (2004) Effect of zinc-alpha2-glycoprotein (ZAG) on expression of uncoupling proteins in skeletal muscle and adipose tissue. Cancer Lett 212: 71-81. (Pubitemid 38887722)
17. Philipp A, Kralisch S, Bachmann A, Lossner U, Kratzsch J, et al (2011) Serum levels of the adipokine zinc-α2-glycoprotein are increased in chronic hemodialysis. Metab Clin Exp 60: 669-672.
18. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Abdalla DSP, et al (2012) Is zinc-α2-glycoprotein a cardiovascular protective factor for patients undergoing hemodialysis? Clin Chim Acta 413: 616-619.
19. Leal VO, Lobo JC, Stockler-Pinto MB, Farage NE, Velarde GC, et al (2012) Zinc-α2-glycoprotein: is there association between this new adipokine and body composition in hemodialysis patients? Ren Fail 34: 1062-1067.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470. (Pubitemid 29135798)
21. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, et al (2010) Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 56: 486-495.
22. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification (2002). Am J Kidney Dis 39: S1-266.
23. Deurenberg P, Weststrate JA, Seidell JC (1991) Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr 65: 105-114.
24. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, et al (2008) A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 73: 391-398. (Pubitemid 351186278)
25. Buron F, Hadj-Aissa A, Dubourg L, Morelon E, Steghens J-P, et al (2011) Estimating glomerular filtration rate in kidney transplant recipients: performance over time of four creatinine-based formulas. Transplantation 92: 1005-1011.
26. Dubourg L, Hadj-Aïssa A, Ferrier B (2010) Adaptation of an enzymatic polyfructosan assay to clinical practice. Anal Biochem 405: 266-268.
27. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
28. Axelsson J, Aström G, Sjölin E, Qureshi AR, Lorente-Cebrián S, et al (2011) Uraemic sera stimulate lipolysis in human adipocytes: role of perilipin. Nephrol Dial Transplant 26: 2485-2491.
29. Ekman R, Johansson BG, Ravnskov U (1976) Renal handling of Zn-alpha2-glycoprotein as compared with that of albumin and the retinol-binding protein. J Clin Invest 57: 945-954.
30. Cirillo M, Anastasio P, De Santo NG (2005) Relationship of gender, age, and body mass index to errors in predicted kidney function. Nephrol Dial Transplant 20: 1791-1798. (Pubitemid 41222590)
31. Guebre-Egziabher F, Bernhard J, Geelen G, Malvoisin E, Hadj-Aissa A, et al (2005) Leptin, adiponectin, and ghrelin dysregulation in chronic kidney disease. J Ren Nutr 15: 116-120. (Pubitemid 40093694)
32. Cumin F, Baum HP, de Gasparo M, Levens N (1997) Removal of endogenous leptin from the circulation by the kidney. Int J Obes Relat Metab Disord 21: 495-504. (Pubitemid 27236969)
33. Pelletier CC, Koppe L, Croze ML, Kalbacher E, Vella RE, et al (2013) White adipose tissue overproduces the lipid-mobilizing factor zinc α2-glycoprotein in chronic kidney disease. Kidney Int 83: 878-886.
34. Rydén M, Agustsson T, Andersson J, Bolinder J, Toft E, et al (2012) Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states. J Intern Med 271: 414-420.
35. Russell ST, Tisdale MJ (2005) The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia. Br J Cancer 92: 876-881. (Pubitemid 40462633)
36. Hassan MI, Waheed A, Yadav S, Singh TP, Ahmad F (2008) Zinc alpha 2-glycoprotein: a multidisciplinary protein. Mol Cancer Res 6: 892-906.
37. Letizia C, Mazzaferro S, De Ciocchis A, Cerci S, Morabito S, et al (1996) Effects of haemodialysis session on plasma beta-endorphin, ACTH and cortisol in patients with end-stage renal disease. Scand J Urol Nephrol 30: 399-402. (Pubitemid 26361742)
38. Bao Y, Bing C, Hunter L, Jenkins JR, Wabitsch M, et al (2005) Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed and secreted by human (SGBS) adipocytes. FEBS Lett 579: 41-47. (Pubitemid 40023371)
39. Gao D, Trayhurn P, Bing C (2010) Macrophage-secreted factors inhibit ZAG expression and secretion by human adipocytes. Mol Cell Endocrinol 325: 135-142.
40. Mracek T, Gao D, Tzanavari T, Bao Y, Xiao X, et al (2010) Downregulation of zinc-{alpha}2-glycoprotein in adipose tissue and liver of obese ob/ob mice and by tumour necrosis factor-alpha in adipocytes. J Endocrinol 204: 165-172.
41. Rubinger D, Backenroth R, Sapoznikov D (2013) Sympathetic nervous system function and dysfunction in chronic hemodialysis patients. Semin Dial 26: 333-343.
42. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, et al (2002) Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105: 1354-1359. (Pubitemid 34260428)
43. Tedeschi S, Pilotti E, Parenti E, Vicini V, Coghi P, et al (2012) Serum adipokine zinc α2-glycoprotein and lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers. Metab Clin Exp 61: 37-42.
44. Olofsson LE, Olsson B, Lystig T, Jacobson P, Jernås M, et al (2010) Preliminary report: Zn-alpha2-glycoprotein genotype and serum levels are associated with serum lipids. Metab Clin Exp 59: 1316-1318.
45. Mracek T, Stephens NA, Gao D, Bao Y, Ross JA, et al (2011) Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients. Br J Cancer 104: 441-447.
46. Schmitt R, Marlier A, Cantley LG (2008) Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol 19: 2375-2383.